<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562729</url>
  </required_header>
  <id_info>
    <org_study_id>zsfdu-obgyn-003</org_study_id>
    <nct_id>NCT02562729</nct_id>
  </id_info>
  <brief_title>Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer</brief_title>
  <official_title>A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1
      radical hysterectomy in cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the rate of postvoid residual urine volume
      (PVR) &lt;50ml on postoperative day 4 in patients with stage IB1 and IIA1 cervix cancer
      underwent complete nerve-sparing type C1 radical hysterectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with fully pelvic nerve plexus preserved</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Proportion of patients who had a postvoid residual urine volume (PVR) under 50ml at postoperative day 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients removing indwelling catheter</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of 36-month local control</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Malignant Neoplasm of Cervix Stage IB1</condition>
  <condition>Stage IIA1 Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Nerve-Sparing Radical Hysterectomy (NSRH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type C1 Hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve-Sparing Radical Hysterectomy</intervention_name>
    <description>Type C1 NSRH Removal indwelling catheter on day 4 after surgery</description>
    <arm_group_label>Nerve-Sparing Radical Hysterectomy (NSRH)</arm_group_label>
    <other_name>Fully Pelvic-Nerve Plexus Preserved</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years to &lt;= 70 years.

          -  Women with histologically confirmed, primary adenocarcinoma or squamous cell carcinoma
             of the uterine cervix.

          -  Stage IIA1, or IB1 disease.

          -  Karnofsky performance status &gt;70.

          -  Patients who comply with follow-up.

          -  With written informed consent.

        Exclusion Criteria:

          -  Age&gt;70

          -  History of lower urinary tract damage or surgery.

          -  With abnormal urodynamic study results.

          -  Karnofsky performance status &lt;70.

          -  Patients who have uncontrolled psychological disorders.

          -  Unwilling to or unable to comply with protocol.

          -  Prior treatment with pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer; Nerve-sparing hysterectomy; simplified</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

